Category Archives: MS Treatment

Featured Article Academic Journal Main Category: Multiple Sclerosis Also Included In: Neurology / Neuroscience;Clinical Trials / Drug Trials Article Date: 02 Nov 2012 - 3:00 PDT Current ratings for: "Rebooting" MS Drug Succeeds In Trials 5 (2 votes) 4.67 (3 votes) Alastair Compston, a professor from the University of Cambridge was principal investigator on both trials and also chaired the Steering Committee that supervised them and an earlier trial. He said in a statement from the University: "Our research shows the transformative effect that alemtuzumab can have for people with MS." The findings mark the conclusion of a unique development program for an MS drug that started in Cambridge in 1991. The statement from the University says: "Never before has an MS drug been tested in clinical outcomes against such a high hurdle, an active first-line drug, in both one phase II trial and two phase III trials; and no drug for MS has been shown to be more effective, in both reducing the risk of disability and reducing the rate of brain atrophy, when compared to another active treatment." MS is an autoimmune disease where the patient's immune system destroys nerve fibers and their protective insulation, the myelin sheath. … Continue reading →

COLORADO SPRINGS, Colo., Nov. 1, 2012 /PRNewswire/ --Cannabis Science Inc., (CBIS) announced today the appointment of Christopher Meenan MS., MBA, as Executive Vice President of Product Research and Development, adding significant expertise to Cannabis Science's investigation of CS-TATI-1 for Karposi's Sarcoma and CS-S/BCC-1 for Basal and Squamous Cell Carcinomas, the Company's lead initiatives entering initial clinical development. Christopher Meenan joins Dr. Roscoe Moore, former U.S. Assistant Attorney General, Dr. Ronald Sekura PhD. former Food and Drug Administration (FDA) Research Chemist, Center for Biologics Evaluation and Review, Dr. Dorothy Bray former Director, Clinical Development HIV, GlaxoSmithKline, UK, and Dr. J. Thomas August Professor, Pharmacology and Molecular Sciences, and Oncology at The Johns Hopkins University School of Medicine. "We are pleased to announce Christopher Meenan's appointment as Vice President of Product Research and Development of Cannabis Science. Mr. Meenan's expertise in drug development will accelerate our investigation of Phytocannabinoids for the treatment of Karposi's Sarcoma and Basal and Squamous Cell Carcinomas," stated, Dr. Robert Melamede, President & CEO, Cannabis Science Inc. Cannabis Science is dedicated to the research and development of phytocannabinoid-based therapeutics. The Company's initial focus is to treat infectious diseases and Cancer. CS-TATI-1, Cannabis Science's lead compound is, in development … Continue reading →

by Tim Gordon kgw.com Posted on November 1, 2012 at 10:30 PM Updated today at 10:30 PM Portland, OR - OHSU Researchers are celebrating their new discovery, they say stands a good chance of helping people suffering from Multiple Sclerosis and a range of other neurological disorders. They've discovered high levels of a particular enzyme not usually found in the brain, only in those with brain damage due to MS, stroke and conditions. Lead researcher Larry Sherman Ph.D. believes if they can figure out how to block the enzyme, the brain can repair itself, where insulating shields around nerve cells have been damaged or destroyed. "We have a chance now of understanding a whole new process that's preventing repair of the brain. And we have the possibility of finding a drug in the next several years that could repair the brain in MS patients and other patients where this nerve sheath is destroyed,"said Sherman. The next step is to find a drug or combination of medicines that block the enzyme. Researchers will first try to find a successful treatment using Japanese Macaque monkeys at the Oregon National Primate Research Center, affiliated with OHSU. The small percentage of the monkeys have … Continue reading →

PARIS (Reuters) - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators. The journal, which published the encouraging results of two late-stage Lemtrada tests on Thursday, also criticized the drugmaker's decision to withdraw leukemia therapy Campath, the same drug given at a different dosage, depriving MS patients who had been using it off-label. In an editorial accompanying the test results, The Lancet voiced concerns that Lemtrada would be priced higher than current MS drugs on the market and said the discontinuation of Campath may mean patients who had used it for MS would not be able to continue their treatment. The injectable drug, chemically known as alemtuzumab, was sold until September 2012 under the name Campath as treatment for leukemia and given more frequently at a higher dosage. "There is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients and health systems," the editorial said. Although Campath remains available free of charge to leukemia patients, Sanofi's rare disease unit Genzyme pulled it off the market in September to prevent … Continue reading →

Rib diagram of the fab fragment of Alemtuzumab drug. Credit: Wikipedia (public domain) Lawrence LeBlond for redOrbit.com Your Universe Online A new drug to fight multiple sclerosis (MS) is showing promise as one of the most effective treatment options ever produced for the debilitating disease, according to UK researchers. The drug, which is used to reboot a persons immune system, has been shown to be effective in MS patients who have already failed to respond to the first drug with which they were treated, as well as those who have gone previously untreated. The promising results of two phase III clinical trials on the new treatment were published today in the journal The Lancet. The researchers, from the University of Cambridge, said this could have significant implications for the some 100,000 people known to have MS in the United Kingdom. Most people diagnosed with MS have the relapsing-remitting version of the disease, in which symptoms can seem to disappear for a time, before suddenly returning. Now, they believe the drug Alemtuzumab, which is used for the treatment of leukemia, may be a beneficial treatment for MS. In leukemia, the drug controls the excess production of white blood cells. In MS … Continue reading →

1 November 2012 Last updated at 05:03 ET By James Gallagher Health and science reporter, BBC News A new drug is the "most effective" treatment for relapsing-remitting multiple sclerosis, say UK researchers. During MS the body's immune system turns on its own nerves causing debilitating muscle problems. Researchers at the University of Cambridge say a cancer drug, which wipes out and resets the immune system, has better results than other options. However, there is concern that a drugs company is about to increase the cost of the drug as a result. Around 100,000 people in the UK have multiple sclerosis. When the condition is diagnosed most will have a form of the disease know as relapsing-remitting MS, in which the symptoms can almost disappear for a time, before suddenly returning. The researchers tested a leukaemia drug, alemtuzumab, which had shown benefits for MS in small studies. In leukaemia, a blood cancer, it controls the excess production of white blood cells. In MS patients, the dose eliminates the immune cells entirely, forcing a new immune system to be built from scratch which should not attack the nerves. Two trials, published in the Lancet medical journal, compared the effectiveness of alemtuzumab with … Continue reading →

A drug which is said to "reboot" the immune system has been shown to be an effective treatment for multiple sclerosis (MS), a study has found. The results of the trials were so encouraging in reducing the number of attacks in those affected that the MS Society is campaigning for the drug to become available on the NHS. The research showed that alemtuzumab significantly reduced the number of attacks or relapses by people with MS compared with the current drug interferon beta-1a which is known commercially as Rebif. This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS, found the study published in the journal The Lancet. In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment. Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse. The study, sponsored by Genzyme and Bayer Schering Pharma, found that alemtuzumab also reduced the risk of acquiring disability by 42% compared with interferon. Disability worsened in 20% of interferon … Continue reading →

Alemtuzumab Lessens Relapses, Improves Disability By Salynn Boyles WebMD Health News Reviewed by Louise Chang, MD Oct. 31, 2012 -- Two new trials offer proof that a leukemia drug long used to treat multiple sclerosis works better than a common treatment. When compared with the widely used drug interferon beta, the leukemia drug alemtuzumab reduced relapse rates by half, researchers say. Alemtuzumab has been used to treat MS for close to two decades, but it has never been approved for this use. It is given by IV infusion. The drug not only reduced relapses, but improved disability associated with MS, such as loss of coordination or difficulty walking, in some patients. Side effects include infusion reactions, infections, and potentially serious autoimmune disorders. Patients taking it must be followed closely. "In the menu of treatment choices for MS patients, I think alemtuzumab falls into the 'high-reward, high-risk' category," says Alasdair Coles, MD, of Britain's University of Cambridge, who led one of the newly published studies. "No other drug has been shown to offer the benefits in terms of disability improvement that this drug shows," he says. "It comes with problems, but these problems are manageable." Read the original post: Leukemia Drug … Continue reading →

Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 2 of 3 Stem cell Treatment protocol for autoimmune diseases such as rheumatoid arthritis. Why stem cells must be administered systemically for autoimmune diseases. Dr. Paz elaborates on the disadvantages of same-day fat-derived stem cell treatments. He presents the scientific rationale for treating rheumatoid arthritis (RA) with fat-derived stem cells along with a published case report including patient video. Presentation of similarities between MS and RA and how MS is treated with a combination of human umbilical cord-derived stem cells and adipose stem cells. Dr. Paz discusses why MS treatment includes umbilical cord-derived stem cells.From:cellmedicineViews:300 3ratingsTime:09:48More inScience Technology Visit link: Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 2 of 3 - Video … Continue reading →

Chronic Fatigue Remedies Specialist http://www.simplyhealingclinic.com - Simply Healing Clinic is devoted to providing responsible information on chronic fatigue remedies specialist, herbal treatments for depression, pain alternative therapy, pain management drugs, natural healing clinic, alternative MS treatment, natural medicine for anxiety, chronic fatigue remedy, alternative medicine, ALS, menopause, endometriosis, hep c natural treatment, PMS, anxiety, lupus, psoriasis, dementia, and depression natural cure.From:Andrew SebestinViews:25 0ratingsTime:01:04More inPeople Blogs Here is the original post: Chronic Fatigue Remedies Specialist - Video … Continue reading →